A detailed history of Hsbc Holdings PLC transactions in Replimune Group, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 29,344 shares of REPL stock, worth $326,598. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,344
Previous 12,272 139.11%
Holding current value
$326,598
Previous $100,000 164.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$5.01 - $9.46 $85,530 - $161,501
17,072 Added 139.11%
29,344 $264,000
Q1 2024

May 15, 2024

SELL
$6.87 - $9.31 $77,356 - $104,830
-11,260 Reduced 47.85%
12,272 $100,000
Q4 2023

Feb 12, 2024

BUY
$6.75 - $16.18 $25,744 - $61,710
3,814 Added 19.34%
23,532 $198,000
Q3 2023

Nov 13, 2023

BUY
$15.96 - $22.18 $98,058 - $136,273
6,144 Added 45.26%
19,718 $337,000
Q2 2023

Aug 11, 2023

BUY
$15.65 - $24.1 $212,433 - $327,133
13,574 New
13,574 $315,000

Others Institutions Holding REPL

About Replimune Group, Inc.


  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $549M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track This Portfolio

Track Hsbc Holdings PLC Portfolio

Follow Hsbc Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.